Review the latest evidence on HER2 testing, clinical implications of HER2-low status in advanced breast cancer, and mastering the safety profile of antibody-drug conjugates, including current guidelines and expert’s recommendations.
Download this short summary slideset of key takeaways from a live satellite symposium on new developments in precision care for advanced HER2-low breast cancer.
In this on-demand webcast from a live symposium, Nadia Harbeck, MD, PhD; Komal Jhaveri, MD; and Heather McArthur, MD, MPH, discuss current guidelines for the assessment of HER2 status in advanced breast cancer, including expanding the spectrum of HER2 positivity and mastering the use and safety of novel antibody–drug conjugates.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.